NEW YORK, NY / ACCESSWIRE / February 1, 2017 / The Biotech Industry has outperformed the broader markets in 2017, despite all the criticism drug makers have been facing. The iShares NASDAQ Biotechnology Index ETF gained 2.84 percent to close at 278.07, up 4.78 percent year-to-date, while the SPDR S&P Biotech ETF spiked 4.14 percent to close at 64.90, up 9.65 percent year-to-date. In comparison, the Dow Jones Industrial Average and the S&P 500 Index have posted gains of 0.51 percent and 1.79 percent, respectively, so far this year. The Biotech Industry received a boost Tuesday after President Trump stated he would loosen drug regulations and push for a faster drug approval process.

Register with us now for your free membership and gain access to our latest research reports at: RDInvesting.com

"We're also gonna be streamlining the process so that, from your standpoint, when you have a drug, you can actually get it approved if it works instead of waiting for many, many years," President Trump said. "The U.S. drug companies have produced extraordinary results for our country, but the pricing has been astronomical for our country."

The U.S. Food and Drug Administration (FDA) approved just 22 new drugs in 2016, less than half of the 45 new drugs approved in 2015, according to Reuters. The number of drugs approved last year was the lowest number of approvals since 2010.

MannKind Corporation (NASDAQ: MNKD)

Get Your Up-To-Date MannKind Research Report Click Here

MannKind's shares spiked 9.61 percent to close at $0.704 a share Tuesday. The stock traded between $0.64 and $0.70 on volume of 5.29 million shares traded. MannKind is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. The company has scheduled an investor conference call to discuss company developments at 5:00 PM (Eastern Time) on February 1, 2017.

The company has recognized total revenue of $162.4 million for the third quarter of 2016, of which recognized revenue from termination of its agreement with Sanofi was $161.8 million consisting of the upfront payment of $150.0 million, milestone payments of $50.0 million, net of $64.8 million of net loss share with Sanofi, as well as $17.4 million in sales of Afrezza and $9.2 million in sales of raw insulin, both to Sanofi. On January 9th, MannKind confirmed that it received $30.6 million from Sanofi on January 6, 2017, representing the balance of the accelerated insulin "put" option previously exercised by MannKind.

Keryx Biopharmaceuticals (NASDAQ: KERX)

Get Your Up-To-Date Keryx Biopharmaceuticals Research Report Click Here

Keryx Biopharmaceuticals' shares jumped 8.71 percent to close at $4.99 a share Tuesday. The stock traded between $4.47 and $5.05 on volume of 2.27 million shares traded. Keryx is a commercial stage company focused on bringing innovative medicines to people with renal disease. On January 12th, the company announced the publication of results from its pivotal Phase 3 study evaluating ferric citrate for iron deficiency anemia (IDA) in non-dialysis-dependent chronic kidney disease (NDD-CKD) in the online issue of the Journal of the American Society of Nephrology (JASN).

"The results shown in this pivotal study demonstrated that ferric citrate, if approved for this indication, could provide an important new treatment option for people living with chronic kidney disease and iron deficiency anemia who are not on dialysis," said Steven Fishbane, M.D., chief of nephrology for North Shore University Hospital and Long Island Jewish Medical Center.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com